July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Clinical Study of Squalamine Lactate Ophthalmic Solution 0.2% in Combination with Ranibizumab Compared to Ranibizimab Monotherapy in Treatment Naive Neovascular Age-Related Macular DegenerationClinical Study of Squalamine Lactate Ophthalmic Solution 0.2% in Combination with Ranibizumab Compared to Ranibizimab Monotherapy in Treatment Naive Neovascular Age-Related Macular Degeneration
Author Affiliations & Notes
  • Michael J Elman
    Elman Retina Group PA, Baltimore, Maryland, United States
  • David M Brown
    Retina Consultants of Houston, Houston, Texas, United States
  • Peter K Kaiser
    Cleveland Clinic, Cleveland, Ohio, United States
  • Jason S Slakter
    Ohr Pharmaceutical, Inc, New York, New York, United States
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4950. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michael J Elman, David M Brown, Peter K Kaiser, Jason S Slakter; Clinical Study of Squalamine Lactate Ophthalmic Solution 0.2% in Combination with Ranibizumab Compared to Ranibizimab Monotherapy in Treatment Naive Neovascular Age-Related Macular DegenerationClinical Study of Squalamine Lactate Ophthalmic Solution 0.2% in Combination with Ranibizumab Compared to Ranibizimab Monotherapy in Treatment Naive Neovascular Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4950.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : We performed a prospective clinical trial to determine if squalamine lactate ophthalmic solution, 0.2% (Squalamine) used in combination with ranibizumab provides better outcomes than ranibizumab monotherapy in patients with treatment naive exudative AMD.

Methods : Prospective, randomized, double-masked, multi-center trial of treatment naïve subjects with newly diagnosed neovascular AMD. Entry criteria included best corrected visual acuity of 24-73 ETDRS letters (20/320 – 20/40 Snellen equivalent), total lesion size up to 30.5 square millimeters (12 MPS disc areas), any type of CNV, but any occult CNV, if present, must measure less than 10 square millimeters on fluorescein angiography. Subjects were randomized 1:1 to receive either Squalamine drops or placebo drops twice a day for the full nine-month study duration. All subjects received monthly intravitreal injections of ranibizumab. The primary efficacy endpoint is a measure of visual acuity gain at week 36.

Results : Over 200 subjects were enrolled in the study. Results of visual acuity and safety outcomes will be reported.

Conclusions : The results of this trial will provide data regarding the potential of Squalamine, a topical, small molecule, multi-target angiogenesis inhibitor, to improve outcomes when used in combination with anti-VEGF injections.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×